JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, J. M.
Right arrow Articles by Fleckenstein, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, J. M.
Right arrow Articles by Fleckenstein, A. E.

Vol. 296, Issue 3, 762-767, March 2001

Regulation of the Vesicular Monoamine Transporter-2: A Novel Mechanism for Cocaine and Other Psychostimulants

Jeffrey M. Brown, Glen R. Hanson and Annette E. Fleckenstein

Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah

The plasmalemmal dopamine (DA) transporter (DAT) is a principal site of action for cocaine. This report presents the novel finding that in addition to inhibiting DAT function, cocaine administration rapidly alters vesicular DA transport. Specifically, cocaine treatment abruptly and reversibly increased both the Vmax of DA uptake and the Bmax of vesicular monoamine transporter-2 (VMAT-2) ligand (dihydrotetrabenazine) binding, as assessed ex vivo in purified rat striatal synaptic vesicles. Selective inhibitors of the DAT (amfonelic acid and GBR12935), but not the plasmalemmal serotonin transporter (fluoxetine), also increased vesicular DA uptake. Moreover, DA depletion resulting from administration of the tyrosine hydroxylase inhibitor alpha -methyl-p-tyrosine had cocaine-like effects. Conversely, administration of the DA-releasing agent methamphetamine rapidly decreased vesicular uptake. Taken together, these data demonstrate for the first time ex vivo that cocaine treatment rapidly alters vesicular monoamine transport, and suggest that alterations in cytoplasmic DA concentrations contribute to stimulant-induced changes in vesicular DA uptake. Hence, the VMAT-2 may be an important target for developing strategies to treat not only cocaine addiction but also other disorders involving alterations in neuronal DA disposition, including Parkinson's disease.

0022-3565/01/2963-0762$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
D. K. Miller, P. A. Crooks, G. Zheng, V. P. Grinevich, S. D. Norrholm, and L. P. Dwoskin
Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular Monoamine Transporters
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1035 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. Nakajima, K. Yamada, T. Nagai, T. Uchiyama, Y. Miyamoto, T. Mamiya, J. He, A. Nitta, M. Mizuno, M. H. Tran, et al.
Role of Tumor Necrosis Factor-{alpha} in Methamphetamine-Induced Drug Dependence and Neurotoxicity
J. Neurosci., March 3, 2004; 24(9): 2212 - 2225.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
D. C. Mash, Q. Ouyang, J. Pablo, M. Basile, S. Izenwasser, A. Lieberman, and R. J. Perrin
Cocaine Abusers Have an Overexpression of alpha -Synuclein in Dopamine Neurons
J. Neurosci., April 1, 2003; 23(7): 2564 - 2571.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein
Methylphenidate Redistributes Vesicular Monoamine Transporter-2: Role of Dopamine Receptors
J. Neurosci., October 1, 2002; 22(19): 8705 - 8710.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. Brown, E. L. Riddle, V. Sandoval, R. K. Weston, J. E. Hanson, M. J. Crosby, Y. V. Ugarte, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
A Single Methamphetamine Administration Rapidly Decreases Vesicular Dopamine Uptake
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 497 - 501.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. P. Hansen, E. L. Riddle, V. Sandoval, J. M. Brown, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Methylenedioxymethamphetamine Decreases Plasmalemmal and Vesicular Dopamine Transport: Mechanisms and Implications for Neurotoxicity
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1093 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. Brown, G. R. Hanson, and A. E. Fleckenstein
Cocaine-Induced Increases in Vesicular Dopamine Uptake: Role of Dopamine Receptors
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1150 - 1153.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.